241 related articles for article (PubMed ID: 10582774)
1. Aromatase inhibitors in the treatment of postmenopausal breast cancer.
Bajetta E; Zilembo N; Bichisao E
Drugs Aging; 1999 Oct; 15(4):271-83. PubMed ID: 10582774
[TBL] [Abstract][Full Text] [Related]
2. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Michaud LB; Buzdar AU
Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
[TBL] [Abstract][Full Text] [Related]
3. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
4. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Hamilton A; Piccart M
Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
[TBL] [Abstract][Full Text] [Related]
5. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Lamb HM; Adkins JC
Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
[TBL] [Abstract][Full Text] [Related]
6. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
7. [Aromatase inhibitors].
Feutrie ML; Bonneterre J
Bull Cancer; 1999 Oct; 86(10):821-7. PubMed ID: 10572233
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of aromatase inhibitors in the treatment of breast cancer.
Harvey HA
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
[TBL] [Abstract][Full Text] [Related]
9. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Wiseman LR; Adkins JC
Drugs Aging; 1998 Oct; 13(4):321-32. PubMed ID: 9805213
[TBL] [Abstract][Full Text] [Related]
10. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
de Jong PC; Blijham GH
Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
Goss PE; Strasser K
Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
[TBL] [Abstract][Full Text] [Related]
12. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
[TBL] [Abstract][Full Text] [Related]
13. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Goss PE; Winer EP; Tannock IF; Schwartz LH
J Clin Oncol; 1999 Jan; 17(1):52-63. PubMed ID: 10458218
[TBL] [Abstract][Full Text] [Related]
15. Pivotal trials of letrozole: a new aromatase inhibitor.
Smith IE
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):41-4. PubMed ID: 9556791
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer.
Tamaki Y; Miyoshi Y; Kim SJ; Tanji Y; Taguchi T; Noguchi S
Expert Rev Anticancer Ther; 2003 Apr; 3(2):193-201. PubMed ID: 12722879
[TBL] [Abstract][Full Text] [Related]
17. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
18. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Wiseman LR; Goa KL
Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
[TBL] [Abstract][Full Text] [Related]
19. [Current status and prospectives of aromatase inhibitors in the treatment of advanced breast cancer].
Boccardo F
Minerva Ginecol; 1998 Mar; 50(3):51-63. PubMed ID: 9595916
[TBL] [Abstract][Full Text] [Related]
20. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]